Rifaximin, gut microbes and mucosal inflammation: Unraveling a complex relationship

Gut Microbes

Volumn 5, Issue 4, 2014, Pages 571-575

  Gao, Jun ^a   Gillilland, Merritt G ^a   Owyang, Chung ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Gut microbiota; Inflammatory cytokines; Irritable bowel syndrome; Lactobacillus; Psychological stress; Segmented filamentous bacteria; Tight junction protein

Indexed keywords

CD3 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; NEOMYCIN; RIFAXIMIN; TIGHT JUNCTION PROTEIN; TUMOR NECROSIS FACTOR; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; IMMUNOLOGIC FACTOR; RIFAMYCIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL LOAD; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CHRONIC STRESS; CLINICAL OUTCOME; CONTROLLED STUDY; DYSBIOSIS; FECES ANALYSIS; GENE EXPRESSION; GENE SEQUENCE; HEPATIC ENCEPHALOPATHY; HYPERALGESIA; IMMOBILIZATION STRESS; INTESTINE FLORA; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; LACTOBACILLUS; MENTAL STRESS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PYROSEQUENCING; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASOMOTOR REFLEX; ANIMAL; BACTERIUM; BIOTA; DISEASE MODEL; DRUG EFFECTS; GASTROINTESTINAL TRACT; IMMUNOLOGY; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MICROBIOLOGY; PATHOLOGY; TREATMENT OUTCOME; WISTAR RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BACTERIA; BIOTA; DISEASE MODELS, ANIMAL; GASTROINTESTINAL TRACT; IMMUNOLOGIC FACTORS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; RATS, WISTAR; RIFAMYCINS; TREATMENT OUTCOME;

EID: 84930278815     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.4161/gmic.32130     Document Type: Article

References (49)

1. Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101:927-34 PMID:1889716
2. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38:1569-80 PMID:8359066; http:// dx.doi.org/10.1007/BF01303162
3. Saito YA, Locke GR, Talley NJ, Zinsmeister AR, Fett SL, Melton LJ 3rd. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000; 95:2816-24 PMID:11051354; http://dx.doi.org/10.1111/j.1572-0241.2000.03192.x
4. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Corinaldesi R. A role for inflammation in irritable bowel syndrome? Gut 2002; 51(Suppl 1):i41-4 PMID:12077063; http://dx.doi.org/10.1136/gut.51. suppl_1.i41
5. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005; 307:1920-5 PMID:15790845; http://dx.doi. org/10.1126/science.1106442
6. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122:1778-83 PMID:12055584; http://dx.doi. org/10.1053/gast.2002.33579
7. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003; 124:1662-71 PMID:12761724; http://dx.doi.org/10.1016/ S0016-5085(03)00324-X
8. Barbara G, Stanghellini V, De Giorgio R, Corinaldesi R. Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil 2006; 18:6-17 PMID:16371078; http:// dx.doi.org/10.1111/j.1365-2982.2005.00685.x
9. Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, McKendrick MW, Moochhala SM. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003; 52:523-6 PMID:12631663; http://dx.doi. org/10.1136/gut.52.4.523
10. Dinan TG, Quigley EM, Ahmed SM, Scully P, O’Brien S, O’Mahony L, O’Mahony S, Shanahan F, Keeling PW. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130:304-11 PMID:16472586; http://dx.doi. org/10.1053/j.gastro.2005.11.033
11. Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, Spiller RC. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006; 101:1288-94 PMID:16771951; http://dx.doi. org/10.1111/j.1572-0241.2006.00672.x
12. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009; 146:41-6 PMID:19595511; http://dx.doi.org/10.1016/j. pain.2009.06.017
13. Ji S, Park H, Lee D, Song YK, Choi JP, Lee SI. Post-infectious irritable bowel syndrome in patients with Shigella infection. J Gastroenterol Hepatol 2005; 20:381-6 PMID:15740480; http://dx.doi. org/10.1111/j.1440-1746.2005.03574.x
14. Quigley EM. Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. J Dig Dis 2007; 8:2-7 PMID:17261128; http://dx.doi.org/10.1111/j.1443-9573.2007.00277.x
15. Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007; 56:802-8 PMID:17148502; http://dx.doi. org/10.1136/gut.2006.108712
16. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133:24-33 PMID:17631127; http://dx.doi. org/10.1053/j.gastro.2007.04.005
17. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22:512-9, e114-5 PMID:19903265
18. Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141:1792-801 PMID:21820992; http://dx.doi.org/10.1053/j. gastro.2011.07.043
19. Jeffery IB, O’Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, Simrén M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61:997-1006 PMID:22180058; http://dx.doi.org/10.1136/ gutjnl-2011-301501
20. Nobaek S, Johansson ML, Molin G, Ahrné S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95:1231-8 PMID:10811333; http://dx.doi.org/10.1111/j.1572-0241.2000.02015.x
21. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95:3503-6 PMID:11151884; http://dx.doi. org/10.1111/j.1572-0241.2000.03368.x
22. O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128:541-51 PMID:15765388; http://dx.doi. org/10.1053/j.gastro.2004.11.050
23. Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005; 22:387-94 PMID:16128676; http://dx.doi. org/10.1111/j.1365-2036.2005.02579.x
24. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59:325-32 PMID:19091823; http://dx.doi.org/10.1136/ gut.2008.167270
25. Ait-Belgnaoui A, Han W, Lamine F, Eutamene H, Fioramonti J, Bueno L, Theodorou V. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut 2006; 55:1090-4 PMID:16507583; http:// dx.doi.org/10.1136/gut.2005.084194
26. Eutamene H, Lamine F, Chabo C, Theodorou V, Rochat F, Bergonzelli GE, Corthésy-Theulaz I, Fioramonti J, Bueno L. Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats. J Nutr 2007; 137:1901-7 PMID:17634262
27. Huang DB, DuPont HL. Rifaximin--a novel antimicrobial for enteric infections. J Infect 2005; 50:97-106 PMID:15667909; http://dx.doi.org/10.1016/j. jinf.2004.05.019
28. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006; 73(Suppl 1):13-27 PMID:16498249; http://dx.doi. org/10.1159/000089776
29. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364:22-32 PMID:21208106; http://dx.doi.org/10.1056/ NEJMoa1004409
30. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 145:557-63 PMID:17043337; http://dx.doi. org/10.7326/0003-4819-145-8-200610170-00004
31. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and metaanalysis. Am J Gastroenterol 2012; 107:28-35, quiz 36 PMID:22045120; http://dx.doi.org/10.1038/ ajg.2011.355
32. Bennett EJ, Tennant CC, Piesse C, Badcock CA, Kellow JE. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut 1998; 43:256-61 PMID:10189854; http://dx.doi. org/10.1136/gut.43.2.256
33. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44:400-6 PMID:10026328; http://dx.doi.org/10.1136/ gut.44.3.400
34. Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, Martínez C, Casellas F, Saperas E, Malagelada JR. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56:203-9 PMID:17005763; http:// dx.doi.org/10.1136/gut.2006.100594
35. O’Mahony SM, Marchesi JR, Scully P, Codling C, Ceolho AM, Quigley EM, Cryan JF, Dinan TG. Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol Psychiatry 2009; 65:263-7 PMID:18723164; http://dx.doi. org/10.1016/j.biopsych.2008.06.026
36. Bailey MT, Dowd SE, Parry NM, Galley JD, Schauer DB, Lyte M. Stressor exposure disrupts commensal microbial populations in the intestines and leads to increased colonization by Citrobacter rodentium. Infect Immun 2010; 78:1509-19 PMID:20145094; http://dx.doi.org/10.1128/IAI.00862-09
37. Bradesi S, Schwetz I, Ennes HS, Lamy CM, Ohning G, Fanselow M, Pothoulakis C, McRoberts JA, Mayer EA. Repeated exposure to water avoidance stress in rats: a new model for sustained visceral hyperalgesia. Am J Physiol Gastrointest Liver Physiol 2005; 289:G42-53 PMID:15746211; http://dx.doi. org/10.1152/ajpgi.00500.2004
38. Xu D, Gao J, Gillilland M 3rd, Wu X, Song I, Kao JY, Owyang C. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology 2014; 146:484, e4 PMID:24161699; http://dx.doi.org/10.1053/j.gastro.2013.10.026
39. Sun Y, Zhang M, Chen CC, Gillilland M 3rd, Sun X, El-Zaatari M, Huffnagle GB, Young VB, Zhang J, Hong SC, et al. Stress-induced corticotropinreleasing hormone-mediated NLRP6 inflammasome inhibition and transmissible enteritis in mice. Gastroenterology 2013; 144:1478-87, e1-8 PMID:23470617; http://dx.doi.org/10.1053/j. gastro.2013.02.038
40. Bailey MT, Dowd SE, Galley JD, Hufnagle AR, Allen RG, Lyte M. Exposure to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation. Brain Behav Immun 2011; 25:397-407 PMID:21040780; http://dx.doi.org/10.1016/j.bbi.2010.10.023
41. Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 2009; 136:2003-14 PMID:19457424; http://dx.doi.org/10.1053/j. gastro.2009.01.075
42. Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palù G, Martines D. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007; 292:G518-25 PMID:17023554; http://dx.doi.org/10.1152/ ajpgi.00024.2006
43. Zareie M, Johnson-Henry K, Jury J, Yang PC, Ngan BY, McKay DM, Soderholm JD, Perdue MH, Sherman PM. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut 2006; 55:1553-60 PMID:16638791; http://dx.doi. org/10.1136/gut.2005.080739
44. Borruel N, Carol M, Casellas F, Antolín M, de Lara F, Espín E, Naval J, Guarner F, Malagelada JR. Increased mucosal tumour necrosis factor alpha production in Crohn’s disease can be downregulated ex vivo by probiotic bacteria. Gut 2002; 51:659-64 PMID:12377803; http://dx.doi.org/10.1136/ gut.51.5.659
45. Llopis M, Antolin M, Carol M, Borruel N, Casellas F, Martinez C, Espín-Basany E, Guarner F, Malagelada JR. Lactobacillus casei downregulates commensals’ inflammatory signals in Crohn’s disease mucosa. Inflamm Bowel Dis 2009; 15:275-83 PMID:18839424; http://dx.doi.org/10.1002/ ibd.20736
46. Thomas CM, Hong T, van Pijkeren JP, Hemarajata P, Trinh DV, Hu W, Britton RA, Kalkum M, Versalovic J. Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling. PLoS One 2012; 7:e31951 PMID:22384111; http://dx.doi.org/10.1371/journal. pone.0031951
47. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139:485-98 PMID:19836068; http://dx.doi.org/10.1016/j.cell.2009.09.033
48. Talham GL, Jiang HQ, Bos NA, Cebra JJ. Segmented filamentous bacteria are potent stimuli of a physiologically normal state of the murine gut mucosal immune system. Infect Immun 1999; 67:1992-2000 PMID:10085047
49. Ait-Belgnaoui A, Bradesi S, Fioramonti J, Theodorou V, Bueno L. Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase. Pain 2005; 113:141-7 PMID:15621374; http://dx.doi.org/10.1016/j.pain.2004.10.002